Cancer ImmunotherapyConfirmed
Some Early CAR-T Lymphoma Patients Are Still Relapse-Free 10 Years Later
Penn's decade-long follow-up gives CAR-T cure language a stronger footing for a subset of lymphoma patients, while showing why not everyone should be promised the same outcome.
Why now
A 10-year follow-up gives CAR-T storytelling the missing timeline: not just response, but durable remission in some of the earliest lymphoma patients treated.
- Overclaim risk
- medium-high
- Primary source
- Official
- Published
- Jun 27, 2026